GlassScriptPhysician profile
Jennifer M Kleinbart
NPI 1952404824
$4,163.35
in general payments reported to CMS, 2019-2025
27 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $143 · 2021: $44.36 · 2022: $501 · 2023: $1,011 · 2024: $1,007 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $783.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $629.93 | 2021-2025 | |
| Pfizer INC. | $576.26 | 2020-2025 | |
| Lilly USA, LLC | $463.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $259.54 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $231.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $221.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $145.35 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $121.88 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.32 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $94.05 | 2023-2025 | |
| Abbott Laboratories | $59.15 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $55.29 | 2020-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $55.19 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $51.00 | 2023-2024 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.50 | 2024-2025 | Zoryve, Livalo |
| Exact Sciences Corporation | $42.18 | 2023-2024 | Cologuard Collection Kit |
| Topcon Healthcare Solutions, INC. | $32.54 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.27 | 2022 | |
| Phathom Pharmaceuticals, INC. | $28.40 | 2025 | Voquezna |
| Ibsa Pharma INC. | $18.62 | 2023 | Tirosint, Licart |
| Shield Therapeutics INC | $17.04 | 2025 | |
| Amarin Pharma, INC. | $16.79 | 2020 | |
| Genentech USA, INC. | $15.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.11 | 2019 | |
| Allergan, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kleinbart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.